TG Therapeutics Inc (NASDAQ: TGTX) has reported E.P.S. of $-0.10 for its fourth fiscal quarter (ending December 31) versus $-0.39 for the same period a year ago. This result exceeded the consensus estimate of $-0.11 by $0.01. E.P.S. were $0.09 for the latest four quarters through December 31 versus $-1.46 for the same period a year ago.
Recent Price Action
On 2/28/24, TG Therapeutics Inc (NASDAQ: TGTX) stock enjoyed a major increase of 26.7%, closing at $17.63. Moreover, exceptionally high trading volume at 315% of normal accompanied the advance. The stock has risen 33.3% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, TGTX is expected to continue to be a modest Value Eraser.
TG Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. TG Therapeutics has a poor Power Rating of 19 and a very low Appreciation Score of 1, triggering the Lowest Value Trend Rating.
Rating Review
In light of this new information and very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment